Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus PHOSLYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus PHOSLYRA.
PHOSLO vs PHOSLYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Renal 100% as unchanged drug, no biliary or fecal elimination.
Category C
Category C
Phosphate Binder
Phosphate Binder